Thiol drugs decrease SARS-CoV-2 lung injury in vivo, disrupt SARS-CoV-2 spike complex binding to ACE2 in vitro

 Authors: Kritika Khanna1 , Wilfred Raymond1 , Jing Jin3 , Annabelle R. Charbit1 , Irina Gitlin1 , Monica Tang2 , Adam D. Werts5 , Edward G. Barrett5 , Jason M. Cox5 , Sharla M. Birch5 , Rachel Martinelli3 , Hannah S. Sperber3 , Sergej Franz3 , Satish Pillai3,4, Anne Marie Healy6,7, Thomas Duff8 , Stefan Oscarson8 , Markus Hoffmann9,10, Stefan Pöhlmann9, 10, Graham Simmons3,4, and John V. Fahy1,2*.

doi: https://doi.org/10.1101/2020.12.08.415505

PDF: https://www.biorxiv.org/content/10.1101/2020.12.08.415505v2.full.pdf

One Sentence Summary: 

The effect of cysteamine to decrease SARS-CoV-2 pneumonia in vivo and of multiple thiol drugs to inhibit SARS-CoV-2 infection in vitro provides rationale for clinical trials of thiol drugs in COVID-19. 

Abstract 

Neutrophil-induced oxidative stress is a mechanism of lung injury in COVID-19, and drugs with a functional thiol group (“thiol drugs”), especially cysteamine, have anti-oxidant and antiinflammatory properties that could limit this injury. Thiol drugs may also alter the redox status of the cysteine-rich SARS-CoV-2 spike glycoprotein (SARS-2-S) and thereby disrupt ACE2 binding. Using ACE2 binding assay, reporter virus pseudotyped with SARS-CoV-2 spikes (ancestral and variants) and authentic SARS-CoV-2 (Wuhan-1), we find that multiple thiol drugs inhibit SARS 2-S binding to ACE2 and virus entry into cells. Pseudoviruses carrying variant spikes were less efficiently inhibited as compared to pseudotypes bearing an ancestral spike, but the most potent drugs still inhibited the Delta variant in the low millimolar range. IC50 values followed the order of their cystine cleavage rates and lower thiol pKa values. In hamsters infected with SARS-CoV2, intraperitoneal (IP) cysteamine decreased neutrophilic inflammation and alveolar hemorrhage in the lungs but did not decrease viral infection, most likely because IP delivery could not achieve millimolar concentrations in the airways. These data show that thiol drugs inhibit SARS-CoV-2 infection in vitro and reduce SARS-CoV-2-related lung injury in vivo and provide strong rationale for trials of systemically delivered thiol drugs as COVID-19 treatments. We propose that antiviral effects of thiol drugs in vivo will require delivery directly to the airways to ensure millimolar drug concentrations and that thiol drugs with lower thiol pKa values are most likely to be effective.

https://www.biorxiv.org/content/10.1101/2020.12.08.415505v2.full.pdf